FDA Diagnostic Office Bests ODE In Decision Times, And Communication
This article was originally published in The Gray Sheet
Executive Summary
510(k)-route diagnostic, imaging and radiation therapy systems may, on average, be in a better position to reach the market a bit sooner than other device types, according to an independent analysis by Booz Allen Hamilton. The reason, says the consulting firm: early and frequent communications by FDA’s diagnostics office.
You may also be interested in...
Big Uptick In Withdrawn 510(k)s Highlighted In Booz Allen Assessment
The consulting group issued its final assessment of FDA’s device review program following a year-long examination; it includes 11 recommendations for improvements. Among the new directives that were not included in Booz Allen’s interim report in December: FDA should perform a large study of withdrawn device submissions to figure out how to limit the growing practice.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.